丽珠医药(01513):重组人源化抗 FXI 双特异性抗体注射液获批开展“预防全膝关节置换术后静脉血栓栓塞症”适应症的临床试验

智通财经
Oct 27

智通财经APP讯,丽珠医药(01513)公布,近日,公司子公司珠海市丽珠单抗生物技术有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》(通知书编号:2026LP03262),同意丽珠单抗申报的重组人源化抗 FXI 双特异性抗体注射液开展“预防全膝关节置换术后静脉血栓栓塞症”适应症的临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10